AMYPAD was a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging. AMYPAD was funded by the Innovative Medicines Initiative (IMI) from October 2016 until September 2022.
We aimed to:
- improve the diagnostic work-up of people suspected to have Alzheimer’s disease and their management
- understand the natural history of the disease in a pre-symptomatic stage
- select people for treatment trials aiming at preventing Alzheimer’s disease.
Company Details
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- https://amypad.eu/
- Competitors
- Amsterdam UMC, RespiriTB, The Journal of Nuclear Medicine - JNM, WINKS - With INtentional Kindness and Support, Alzheimer's Diagnosis in Older Adults with Chronic Conditions (ADACC) Network, REAL AD, Amsterdam UMC - Alzheimer Center Amsterdam, Kendall Nicole Eich Foundation, Västra Götalands läkarförening, DYMIC.
Amypad Questions
Amypad's website is https://amypad.eu/
Amypad's LinkedIn profile is https://www.linkedin.com/company/amypad
Amypad's industry is
Research Services
Amypad's top competitors are
Amsterdam Umc,
Respiritb,
The Journal Of Nuclear Medicine - Jnm,
Winks - With Intentional Kindness And Support,
Alzheimer's Diagnosis In Older Adults With Chronic Conditions (Adacc) Network,
Real Ad,
Amsterdam Umc - Alzheimer Center Amsterdam,
Kendall Nicole Eich Foundation,
Västra Götalands Läkarförening,
Dymic.
Amypad's categories are Research Services
